Home >> Top News >> Illumina to buy PacBio for $1.2 billion

Illumina to buy PacBio for $1.2 billion

Print Friendly, PDF & Email

Nov. 7, 2018Illumina announced it will acquire Pacific Biosciences for approximately $1.2 billion. With this acquisition, Illumina will be positioned to provide integrated workflows and novel innovations that bring together both Illumina’s short-read sequencing platforms with PacBio’s long-read sequencing capabilities to help researchers advance their discoveries faster and clinicians offer new tests economically.

“PacBio’s unmatched accuracy mirrors that of Illumina’s in short-read sequencing. Combining the two technologies positions us to reach more applications, accelerate the pace of genomic discovery and bolster our innovation engine which has been a hallmark of Illumina since our inception,” Francis deSouza, president and CEO of Illumina, said in a press release. “PacBio’s relentless pursuit to improve sequencing accuracy, while driving down the cost, underscores the potential of long-reads to expand sequencing to new customers and applications.”

Illumina expects to close the transaction in mid-2019.


Check Also

Whole genome sequencing library prep kit, 12/17

December 2017—Illumina announced the availability of a whole genome sequencing library prep product, Nextera DNA Flex. The kit enables direct input of blood and saliva samples, eliminating the need for ancillary equipment and reagents to extract DNA and quantify sample concentration prior to sequencing. It also removes steps in the library prep workflow, such as mechanical fragmentation of DNA, quantification, and normalization.